Skip to main content
. 2022 Jan 15;191(6):2569–2577. doi: 10.1007/s11845-021-02885-9

Table 4.

Predicted required LLT for those who completed CR in 2019 (n = 55)

Moderate intensity statin monotherapy 4 (7)
High intensity statin monotherapy 15 (27)
High intensity statin + ezetimibe 14 (25)
PCSK9i + high intensity statin 9 (16)
PCSK9i + high intensity statin + ezetimibe 13 (24)

Table 4 displays the predicted LLT required for those who failed to meet their absolute LDL-C targets upon completion of CR in 2019. Values are displayed as count with percentage of column total in brackets